61

Cabozantinib

61 Publications Verification

Cat. No.: HY-13016

CAS No.: 849217-68-1

Purity: 99.96%

Synonyms: XL184; BMS-907351

Target:

VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis

Research Areas:

Cancer

Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC₅₀ values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC₅₀=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis ^[2].

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

13

Rebastinib

13 Cited Publications

Cat. No.: HY-13024

CAS No.: 1020172-07-9

Purity: 99.91%

Synonyms: DCC-2036

Target:

Bcr-Abl Cytochrome P450 Tie FOXO Src FLT3 Apoptosis

Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor, with IC₅₀ values of 0.8 nM and 4 nM against Abl1 ^WT and Abl1 ^T315I, respectively. Rebastinib potently inhibits CYP2C8 (IC₅₀ = 0.0533 μM) and CYP2C9 (IC₅₀ = 2.54 μM). Rebastinib allosterically inhibits Tie2 with an IC₅₀ of 0.63 nM. Rebastinib inhibits the transcriptional activity of FoxO1. Rebastinib inhibits SRC family kinases, KDR and FLT3 kinases. Rebastinib induces Apoptosis. Rebastinib exerts anti-tumor activity in breast cancer. Rebastinib exerts anti-angiogenic effects. Rebastinib increases myotube diameter and improves reduced contractility. Rebastinib can be used in research related to triple-negative breast cancer, luminal breast cancer, pancreatic neuroendocrine tumors, muscle atrophy, cancer cachexia, chronic myeloid leukemia, and B-lymphocytic leukemia ^[2] .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

8

SU11274

8 Cited Publications

Cat. No.: HY-12014

CAS No.: 658084-23-2

Purity: 98.82%

Synonyms: PKI-SU11274

Target:

c-Met/HGFR Autophagy Apoptosis

Research Areas:

Cancer

SU11274 is a selective Met inhibitor with IC₅₀ of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

Razuprotafib

4 Cited Publications

Cat. No.: HY-109041

CAS No.: 1008510-37-9

Purity: ≥98.0%

Synonyms: AKB-9778

Target:

Phosphatase Tie

Research Areas:

Inflammation/Immunology

Razuprotafib (AKB-9778) is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC₅₀of 17 pM. Razuprotafib promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib inhibits the structurally related phosphatase PTP1B with an IC₅₀ of 780 nM. Razuprotafib shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC₅₀=36 pM) and HPTPγ (100 pM) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

SB-633825

4 Cited Publications

Cat. No.: HY-108333

CAS No.: 956613-01-7

Purity: 98.05%

Target:

Ser/Thr Kinase

Research Areas:

Cardiovascular Disease Cancer

SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC₅₀s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

Razuprotafib sodium

4 Cited Publications

Cat. No.: HY-109041A

CAS No.: 1809275-69-1

Synonyms: AKB-9778 sodium

Target:

Phosphatase Tie

Research Areas:

Inflammation/Immunology

Razuprotafib (AKB-9778) sodium is a potent and selective inhibitor of the catalytic activity of VE-PTP (vascular endothelial protein tyrosine phosphatase) with an IC₅₀of 17 pM. Razuprotafib sodium promotes TIE2 activation, enhances ANG1-induced TIE2 activation, and stimulates phosphorylation of signaling molecules in the TIE2 pathway, including AKT, eNOS, and ERK. Razuprotafib sodium inhibits the structurally related phosphatase PTP1B with an IC₅₀ of 780 nM. Razuprotafib sodium shows excellent selectivity for VE-PTP versus a variety of phosphatases, with the exception of HPTPη (IC₅₀=36 pM) and HPTPγ (100 pM) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

Angiopoietin-2 Protein, Human (HEK293, His)

3 Cited Publications

Cat. No.: HY-P7510

Purity: ≥ 95%, as determined by reducing SDS-PAGE.

Synonyms: ANGPT2; Angiopoietin-2a; Angiopoietin 2; TIE2-Ligand; Ang2; LMPHM10; Angiopoietin-2; AGPT2; Angiopoietin-2B; ANG-2

Species:

Human

Source:

HEK293

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

Pexmetinib

2 Cited Publications

Cat. No.: HY-16782

CAS No.: 945614-12-0

Synonyms: ARRY-614

Target:

Tie p38 MAPK STAT Nuclear Factor of activated T Cells (NFAT) MMP TNF Receptor

Pexmetinib (ARRY-614) is an orally active dual Tie-2 and p38 MAPK inhibitor. Pexmetinib binds to Tie-2 and p38 MAPK in a "DFG-out" conformation, attenuates the phosphorylation of p38, inhibits STAT3 activation, reduces the promoter-binding activity of NFATc1, and decreases the expression of MMPs. Pexmetinib inhibits leukemia cell proliferation, abrogates TNF-α-mediated myelosuppression of healthy hematopoietic stem cells, stimulates hematopoiesis in primary myelodysplastic syndrome (MDS) samples, inhibits RANKL-induced osteoclast formation and bone resorption, and suppresses migration, invasion and induced osteolysis of breast cancer cells. Pexmetinib can be used in research related to myelodysplastic syndrome, acute myeloid leukemia and breast cancer-induced osteolysis ^[2].

Compare

loading...